172050

Anacardic Acid

The Anacardic Acid, also referenced under CAS 16611-84-0, modulates the biological activity of Anacardic. This small molecule/inhibitor is primarily used for Cell Structure applications.

• Sinónimos: Anacardic Acid, AA, 2-Hydroxy-6-pentadecylbenzoic Acid, 6-Pentadecylsalicylic Acid, Aurora Kinase A Activator, Histone Acetyltransferase Inhibitor III, SUMOylation Inhibitor II, HAT Inhibitor III, p300/CBP Inhibitor III, PCAF Inhibitor I
• Fórmula empírica (notación de Hill): C₂₂H₃₆O₃
• Número de CAS: 16611-84-0
• Peso molecular: 348.52
• Número MDL: MFCD07368254
• Código UNSPSC: 12352106
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• Ensayo: ≥95% (HPLC)
• Formulario: solid
• fabricante / nombre comercial: Calbiochem^®
• condiciones de almacenamiento: OK to freeze; protect from light
• color: white
• solubilidad: DMSO: 10 mg/mL; ethanol: 10 mg/mL; methanol: 10 mg/mL
• Condiciones de envío: ambient
• temp. de almacenamiento: 2-8°C
• cadena SMILES: Oc1c(c(ccc1)CCCCCCCCCCCCCCC)C(=O)O
• InChI: 1S/C22H36O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(23)21(19)22(24)25/h15,17-18,23H,2-14,16H2,1H3,(H,24,25)
• Clave InChI: ADFWQBGTDJIESE-UHFFFAOYSA-N

Descripción

Descripción general

A cell-permeable ginkgolic acid (Cat. No. 345887) analog that inhibits protein SUMO (Cat. Nos. 662037, 662039, and 662042) modification (IC₅₀ = 2.2 µM using RanGAP1-C2 as substrate) in an ATP-dependent manner by selectively targeting SUMO-activating enzyme E1 (Cat. Nos. 662073 and 662074) and interfering with E1-SUMO intermediate formation. Both anacardic acid and ginkgolic acid are shown to effectively decrease overall SUMOylation of 293T cellular proteins in a dose-dependent manner, while neither compound is effective in affecting overall cellular protein ubiquitination or histone H4K8 acetylation in 293T cultures, although anacardic acid is shown to inhibit p300 (Cat. No. 506200) and PCAF (Cat. No. 124026) histone acetyltransferase activities in cell-free acetylase assays (by 82% and 86%, respectively, at 10 µM). Also reported to inhibit the activity of prostaglandin synthase, tyrosinase, and lipoxygenase, as well as to enhance Aurora kinase A (Cat. No. 481413), but not Aurora kinase B, autophosphorylation and kinase activity by inducing conformation change and enhancing ATP binding.

Acciones bioquímicas o fisiológicas

Cell permeable: yes

Primary Target
HAT

Product competes with ATP.

Reversible: no

Target IC₅₀: 5 µM against HAT; 8.5 µM against PCAF; 2.2 µM inhibiting protein SUMO modification using RanGAP1-C2 as substrate

Envase

Packaged under inert gas

Advertencia

Toxicity: Standard Handling (A)

Reconstitución

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Otras notas

Fukuda, I., et al. 2009. Chem. Biol.16, 133.
Kishore, A.H. 2008. J. Med. Chem.51, 792.
Balasubramanyam, K., et al. 2003. J. Biol. Chem.278, 19134.
Paramashivappa, R., et al. 2002. J. Agric. Food Chem.50, 7709.

Información legal

Sold under license of U.S. Patent 7,332,629 and related patents.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3